In the News

28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability

In the News
Spotlights
Case Studies

In the News

April 2, 2026
5
min read
Accelerating Organoid Adoption Set to Transform Cancer Drugs
When asked about the biggest obstacles preventing organoids from reaching their full potential, Alif Saleh, CEO of 28bio, emphasizes that adoption, not technology, is the primary hurdle, particularly in drug discovery, where a staggering 95% failure rate is accepted as the norm.
June 9, 2025
4
min read
The Clumps of Brain Cells That Can Play Pac-Man
What they mean for medicine and perhaps the future of AI data centers.
April 30, 2025
2
min read
FDA’s Shift From Animal Testing Opens Doors for Organoid Makers
The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.
More News
Arrow Down Icon
Spotlight

28bioGRANT for Neurodegenerative Disease

The 28bioGRANT for Neurodegenerative Disease is designed to assist academic researchers in their pursuit to understand the human biological underpinnings of these diseases and translate those insights into potential therapeutic strategies.

Spotlights

March 2, 2026
5
min read
28bioGRANT for Neurodegenerative Disease
The 28bioGRANT for Neurodegenerative Disease is designed to assist academic researchers in their pursuit to understand the human biological underpinnings of these diseases and translate those insights into potential therapeutic strategies.
February 5, 2026
7
min read
Organoid Neurotoxicity Testing Embraced by FDA and NIH
Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.
February 5, 2026
7
min read
Modeling Myelination and Therapeutic Response in Demyelinating Disorders
CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.

Subscribe to 28bioNEWS

28bioNEWS is a monthly market intelligence briefing built for those shaping the future of drug discovery and development.
Learn More
Spotlight

Organoid Neurotoxicity Testing Embraced by FDA and NIH

Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.

Case Studies

Case Study
5
min read
Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment
CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Takeda’s Validated Method for CNS Safety

Learn how CNS-3D brain organoids deliver 7.4× better clinical predictivity than animal models in this on-demand webinar with Takeda’s Investigative Toxicology team.
Learn More
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy